- Home
- PBYI vs MRCC Comparison
PBYI vs MRCC Comparison
Compare PBYI & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- MRCC
- Stock Information
- Founded
- PBYI 2010
- MRCC 2011
- Country
- PBYI United States
- MRCC United States
- Employees
- PBYI N/A
- MRCC N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- PBYI Health Care
- MRCC Finance
- Exchange
- PBYI Nasdaq
- MRCC Nasdaq
- Market Cap
- PBYI 171.7M
- MRCC 155.1M
- IPO Year
- PBYI N/A
- MRCC 2012
- Fundamental
- Price
- PBYI $4.34
- MRCC $7.56
- Analyst Decision
- PBYI Strong Buy
- MRCC Hold
- Analyst Count
- PBYI 1
- MRCC 1
- Target Price
- PBYI $7.00
- MRCC $8.00
- AVG Volume (30 Days)
- PBYI 543.3K
- MRCC 73.5K
- Earning Date
- PBYI 11-06-2025
- MRCC 11-11-2025
- Dividend Yield
- PBYI N/A
- MRCC 13.12%
- EPS Growth
- PBYI 434.29
- MRCC N/A
- EPS
- PBYI 0.97
- MRCC 0.09
- Revenue
- PBYI $238,062,000.00
- MRCC $51,229,000.00
- Revenue This Year
- PBYI N/A
- MRCC N/A
- Revenue Next Year
- PBYI N/A
- MRCC N/A
- P/E Ratio
- PBYI $4.51
- MRCC $86.31
- Revenue Growth
- PBYI 8.63
- MRCC N/A
- 52 Week Low
- PBYI $2.32
- MRCC $5.96
- 52 Week High
- PBYI $6.07
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- PBYI 42.81
- MRCC 71.70
- Support Level
- PBYI $4.49
- MRCC $7.41
- Resistance Level
- PBYI $4.72
- MRCC $7.65
- Average True Range (ATR)
- PBYI 0.26
- MRCC 0.12
- MACD
- PBYI -0.12
- MRCC -0.03
- Stochastic Oscillator
- PBYI 3.51
- MRCC 62.96
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.